BioSpace News Archive

F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, announced today that F-star will participate next week at the H. C. Wainwright 23rd Annual Global Investment Conference, taking place virtually September 13-15.

NeuroOne® Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), announces today that management will present at the H.C. Wainwright 23rd Annual Global Investment being held virtually from September 13th to 15th, 2021.

Frontage Laboratories, Inc is a PanaBIOS Trusted Travel Approved COVID-19 Laboratory Testing Provider.

CG Oncology, Inc. today announced a clinical trial collaboration to evaluate the safety and efficacy of CG0070, an oncolytic immunotherapy, in combination with OPDIVO® (nivolumab), Bristol Myers Squibb’s anti-PD-1 therapy, for the treatment of metastatic urothelial cancer in a Phase 1/2 clinical study.

Navigation Sciences announced today that the company has been awarded a $400,000 Phase 1 Small Business Technology Transfer Program (SBIR/STTR) grant from the National Cancer Institute (NCI) to advance the development of a bronchoscope-based tissue marker (NaviSci EndoMarker™) for use in its NaviSci™ Intelligent Surgical System for tissue conserving removal of early-stage lung tumors.

Mammoth Biosciences, the biotech company leveraging the diversity of life to build the next generation of CRISPR products to cure and detect disease, today announced it has secured $195 million in financing, joining the select ranks of “unicorn” startups with a valuation of more than $1 billion.

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences.

Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that members of its executive management team are scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference.

Viewpoint Molecular Targeting, Inc., a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, announced that the U.S. Food and Drug Administration has cleared an Investigational New Drug application to commence a Phase 1 imaging study of VMT-

Vektor Medical, Inc., a private company founded to develop the next-generation in arrhythmia mapping systems, today announced the publication of results of a dual-site study involving its non-invasive vMap™ system during stereotactic ablative radiotherapy (SAbR), in the peer-reviewed journal, Heart Rhythm O2.